Oct 17 (Reuters) – Johnson & Johnson, which completed its $30 billion acquisition of Swiss biotech Actelion in June, reported a 11.9 percent fall in quarterly profit as costs rose.
Continue Reading Below
The company’s net earnings fell to $3.76 billion, or $1.37 per share, in the third quarter from $4.27 billion, or $1.53 per share, a year earlier.
However, the diversified healthcare company’s sales rose 10.3 percent to $19.65 billion in the quarter.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D’Silva)